gsk_boronia_australia

GlaxoSmithKline opens new £56 million facility in Hertfordshire

pharmafile | April 19, 2016 | News story | Manufacturing and Production Andrew Witty, GSK, GlaxoSmithKline, Sir Andrew Witty, ellipta, facility, george freeman, inhalers, manufacturing, new, respiratory, ware 

GlaxoSmithKline has opened a new £56 million manufacturing facility in Hertfordshire, South-East England.

The facility in Ware will create 150 new jobs and will form the new base for the pharma giant’s production of inhalers to use with respiratory medicines. Chief executive of GSK, Sir Andrew Witty, and life sciences minister, George Freeman MP, were given a tour of the facility which produces the Ellipta inhalers.

This is the latest investment in the Ware facility which formed part of a £200 million investment by GSK into its UK facilities.

Witty says: “This new facility demonstrates our commitment to manufacturing in the UK which continues to be a very positive environment for life sciences investment. We currently export Ellipta inhalers from Ware to over 74 countries and the new facility opened today will increase capacity to meet growing demand for our new portfolio of respiratory medicines worldwide.”

Freeman added: “This £56 million investment by GSK is fantastic news for Ware and the UK’s thriving life sciences industry.”

Sean Murray

Related Content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement …

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental …

Ardena announces €20m expansion following first GMP approval

Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch …

Latest content